RxDoctor Payments Data

Dominic Catanese, DPM

Podiatrist · Bronx, NYNPI 1932284239

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (42.9%), education and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Gotham Surgical Solutions & Devices, Inc. at 29.5% of the total. Reporting peaked in 2019 at $4,239 and has fallen 75.7% since, to $1,031 in 2025. Among podiatrist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,452in general payments, 2019–2025

Across 90 payments — averaging $127.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gotham Surgical Solutions & Devices, Inc.$3K
  • Medical Device Business Services, Inc.$2K
  • Linvatec Corporation$1K
  • Paratek Pharmaceuticals, Inc.$897
  • Stryker$482
  • Arthrex$461
  • plus $3K from 13 others

What the payments were for

  • Consulting fees$1,54013%
  • Travel & lodging$2,16519%
  • Food & beverage$4,91043%
  • Education$2,83725%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,452 in reported general payments places this provider in the 95th percentile of 862 podiatrist providers in New York.

See all podiatrist providers in New York

Medicare billing

Part B allowed, 2024
$101,674
Medicare patients
349
Services billed
1,037

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CiclopiroxCiclopirox Olamine385$13,249
SantylCollagenase Clostridium Hist.33$9,936
Ammonium Lactate181$2,885
Diclofenac Sodium34$1,875
Naproxen131$978
Nystatin19$508
Ketoconazole13$467
Terbinafine Hcl66$425
Meloxicam74$149
Methylprednisolone24$131
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen22$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$422$9,93633 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 862 podiatrist providers in New York.

Other podiatrist in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →